Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment

International Journal of Cancer

Volumn 86, Issue 4, 2000, Pages 570-576

  Leech, Siân H ^c   Olie, Robert A ^c   Gautschi, Oliver ^c   Simões Wüst, A Paula ^c   Tschopp, Stefan ^c   Häner, Robert ^a   Hall, Jonathan ^c   Stahel, Rolf A ^c   Zangemeister Wittke, Uwe ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 3; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

APOPTOSIS; BCL-X PROTEIN; CARCINOMA, SMALL CELL; CASPASE 3; CASPASES; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0034071150     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T     Document Type: Article

References (32)

1. ACKERMANN, E.J., TAYLOR, J.E., NARAYANA, R. and BENNETT, C.F., The role of anti-apoptotic bcl-2 family members in endothelial apoptosis elucidated with anti-sense oligonucleotides. J. biol. Chem., 274, 11245-11252 (1999).
2. BAKER, B.F., LOT, S.S., CONDON, T.P., CHENG, F.S., LESNIK, E.A., SASMOR, H.M. and BENNETT, C.F., 2′-O-(2-methoxy)ethyl-modified anti-intercellular-adhesion-molecule-1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical-vein endothelial cells. J. biol. Chem., 272, 11994-12000 (1997).
3. BOJES, H.K., SURESH, P.K., MILLS, E.M., SPITZ, D.R., SIM, J.E. and KEHRER, J.P., bcl-2 and bcl-xL in peroxide-resistant A549 and U87MG cells. Toxicol. Sci., 42, 109-116 (1998).
4. BORING, C.C., SQUIRES, T.S., TONG, T. and MONTGOMERY, S., Cancer statistics, 1994. CA, Cancer J. Clin., 44, 7-26 (1994).
5. CROOKE, S.T., Molecular mechanisms of anti-sense drugs: RNase H. Anti-sense, nucleic acid drug development, 8, 133-134 (1998).
6. DE MESAEKER, A., HÄNER, R., MARTIN, P. and MOSER, H.E., Anti-sense oligonucleotides. Acc. Chem. Res., 28, 366-374 (1995).
7. DIBBERT, B., DAIGLE, I., BRAUN, D., SCHRANZ, C., WEBER, M., BLASER, K., ZANGEMEISTER-WITTKE, U., AKBAR, A.N. and SIMON, H.U., Role for bcl-x(L) in delayed eosinophil apoptosis mediated by granulocyte-macrophage-colony-stimulating factor and interleukin-5. Blood, 92, 778-783 (1998).
8. DOSAKA, A.H., KATABAMI, M., HOMMURA, H., FUJIOKA, Y., KATOH, H. and KAWAKAMI, Y., bcl-2 expression in non-small-cell lung cancers: higher frequency of expression in squamous-cell carcinomas with earlier pT status. Oncology, 56, 259-264 (1999).
9. FISHER, D.E., Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542 (1994).
10. FULDA, S., FRIESEN, C., LOS, M., SCAFFIDI, C., MIER, W., BENEDICT, M., NUNEZ, G., KRAMMER, P.H., PETER, M.E. and DEBATIN, K.M., Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuro-ectodermal tumors. Cancer Res., 57, 4956-4964 (1997).
11. GEWIRTZ, A.M., SOKOL, D.L., and RATAJCZAK, M.Z., Nucleic acid therapeutics: state of the art and future prospects. Blood, 92, 712-736 (1998).
12. GINSBERG, R.J., VOKES, E.E. and RABEN, A., Non-small-cell lung cancer. In: V.T. de Vita, S. Hellmann, Jr. and S.A. Rosenberg (eds.), Cancer: principles and practice of oncology, pp. 858-910, Lippincott-Raven, Philadelphia, New York (1997).
13. GOTTSCHALK, A.R., BOISE, L.H., THOMPSON, C.B. and QUINTANS, J., Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. nat. Acad Sci. (Wash.), 91, 7350-7354 (1994).
14. HANECAK, R., BROWN, D.V., FOX, M.C., AZAD, R.F., FURUSAKO, S., NOZAKI, C., FORD, C., SASMOR, H. and ANDERSON, K.P., Anti-sense oligonucleotide inhibition of hepatitis-C-virus-gene expression in transformed hepatocytes. J. Virol., 70, 5203-5212 (1996).
15. HIGASHIYAMA, M., DOI, O., KODAMA, K., YOKOUCHI, H. and TATEISHI, R., High prevalence of bcl-2-oncoprotein expression in small-cell lung cancer. Anticancer Res., 15, 503-505 (1995).
16. IHDE, D.C., PASS, H.I. and GLATTSTEIN, E.J., Small-cell lung cancer. In: V.T. de Vita, S. Hellmann, Jr. and S.A. Rosenberg (eds.), Cancer: principles and practice of oncology, pp. 911-949, Lippincott-Raven, Philadelphia, New York (1997).
17. IKEGAKI, N., KATSUMATA, M., MINNA, J. and TSUJIMOTO, Y., Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res., 54, 6-8 (1994).
18. JANSEN, B., SCHLAGBAUER-WADL, H., BROWN, B.D., BRYAN, R.N., VAN ELSAS, A., MULLER, M., WOLFF, K., EICHLER, H.G. and PEHAMBERGER, H., bcl-2 anti-sense therapy chemosensitizes human melanoma in SCID mice. Nature Med., 4, 232-234 (1998).
19. JIANG, S.X., SATO, Y., KUWAO, S. and KAMEYA, T., Expression of bcl-2-oncogene protein is prevalent in small-cell lung carcinomas. J. Pathol., 177, 135-138 (1995).
20. KAWASAKI, A.M., CASPER, M.D., FREIER, S.M., LESNIK, E.A., ZOUNES, M.C., CUMMINS, L.L., GONZALEZ, C. and COOK, P.D., Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant anti-sense compounds with high affinity and specificity for RNA targets. J. med. Chem., 36, 831-841 (1993).
21. MARTIN, P., A new access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides. Helv. chim. Acta, 78, 486-504 (1995).
22. MONIA, B.P., LESNIK, E.A., GONZALEZ, C., LIMA. W.F., MCGEE, D., GUINOSSO, C.J., KAWASAKI, A.M., COOK, P.D. and FREIER, S.M., Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as anti-sense inhibitors of gene expression. J. biol. Chem., 268, 14514-14522 (1993).
23. MORGAN, D.M., Tetrazolium (MTT) assay for cellular viability and activity. Methods mol. Biol. 79, 179-183 (1998).
24. OLIE, R.A., DURRIEU, F., CORNILLON, S., LOUGHRAN, G., GROSS, J., EARNSHAW, W.C. and GOLDSTEIN, P., Apparent caspase independence of programmed cell death in Dictyostelium. Curr. Biol., 8, 955-958 (1998).
25. POLLMAN, M.J., HALL, J.L. and GIBBONS, G.H., Determinants of vascular-smooth-muscle-cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circulat. Res., 84, 113-121 (1999).
26. REEVE, J.G., XIONG, J., MORGAN, J. and BLEEHEN, N.M., Expression of apoptosis-regulatory genes in lung-tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Brit. J. Cancer, 73, 1193-1200 (1996).
27. SIMONIAN, P.L., GRILLOT, D.A. and NUNEZ, G., bcl-2 and bcl-xL can differentially block chemotherapy-induced cell death. Blood, 90, 1208-1216 (1997).
28. STEIN, C.A., SUBASINGHE, C., SHINOZUKA, K. and COHEN, J.S., Physiochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res., 16, 3209-3221 (1988).
29. THOMPSON, C.B., Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462 (1995).
30. WEBB, A., CUNNINGHAM, D., COTTER, F., CLARKE, P.A., DISTEFANO, F., ROSS, P., CORBO, M. and DZIEWANOWSKA, Z., bcl-2 anti-sense therapy in patients with non-Hodgkin lymphoma. Lancet, 349, 1137-1141 (1997).
31. ZANGEMEISTER-WITTKE, U., SCHENKER, T., LUEDKE, G.H. and STAHEL, R.A., Synergistic cytotoxicity of bcl-2 anti-sense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell-lung-cancer cell lines. Brit. J. Cancer, 78, 1035-1042 (1998).
32. ZIEGLER, A., LUEDKE, G.H., FABBRO, D., ALTMANN, K.H. and ZANGEMEISTER-WITTKE, U., Induction of apoptosis in small-cell-lung-cancer cells by an anti-sense oligodeoxynucleotide targeting the bcl-2 coding sequence. J. nat. Cancer Inst., 89, 1027-1036 (1997).